Valuation: Norda ASA

Market Cap 513M 54.03M 47.41M 44.78M 40.81M 76.39M 5.18B 76.94M 536M 208M 2.65B 203M 198M 8.5B P/E 2023 *
-
P/E 2024 3.26x
Enterprise Value 264M 27.83M 24.42M 23.07M 21.02M 39.35M 2.67B 39.63M 276M 107M 1.36B 105M 102M 4.38B EV / Sales 2023
-1.24x
EV / Sales 2024 0.4x
Free-Float
6.26%
Yield 2023 *
-
Yield 2024 32.5%
1 day-0.46%
Current month+1.18%
1 month-0.46%
3 months-0.46%
6 months+1.06%
Current year-14.00%
1 month 85
Extreme 85
86.4
Current year 81
Extreme 81
86.4
1 year 81
Extreme 81
100
3 years 41
Extreme 41
100
5 years 41
Extreme 41
100
10 years 8
Extreme 8
100
Manager TitleAgeSince
Chief Executive Officer - 07/04/2013
Director TitleAgeSince
Chairman 54 30/01/2014
Director/Board Member 68 19/06/2013
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-0.46%0.00%+6.17%+109.76% 46.36M
-0.14%+4.33%+9.88%+31.73% 48.01B
-1.69%+1.48%+53.02%+33.59% 45.27B
+2.56%+7.34%+382.17%+594.81% 42.84B
+0.24%+2.85%+9.78%+89.54% 40.93B
-0.62%-1.11%+4.70%+46.02% 29.6B
-0.28%+1.07%+26.83%+152.91% 17.32B
-0.46%+1.20%+26.78%+41.32% 15.34B
-2.21%-4.70% - - 15.15B
+3.37%+9.21%+9.93% - 14.84B
Average +0.03%+1.39%+58.81%+137.46% 26.93B
Weighted average by Cap. +0.08%+1.77%+81.86%+153.91%

Financials

2023 2024
Net sales 86.92M 9.15M 8.03M 7.59M 6.91M 12.94M 877M 13.03M 90.77M 35.16M 448M 34.36M 33.62M 1.44B 372M 39.15M 34.36M 32.45M 29.57M 55.36M 3.75B 55.75M 388M 150M 1.92B 147M 144M 6.16B
Net income 31.17M 3.28M 2.88M 2.72M 2.48M 4.64M 315M 4.67M 32.55M 12.61M 161M 12.32M 12.06M 517M 126M 13.26M 11.64M 10.99M 10.02M 18.75M 1.27B 18.88M 132M 50.94M 649M 49.79M 48.71M 2.09B
Net Debt -311M -32.77M -28.76M -27.16M -24.75M -46.33M -3.14B -46.66M -325M -126M -1.6B -123M -120M -5.16B -249M -26.2M -22.99M -21.71M -19.79M -37.04M -2.51B -37.3M -260M -101M -1.28B -98.37M -96.24M -4.12B
Logo Norda ASA
Norda ASA, formerly NorDiag ASA, is a Norway-based company active within the biotechnology sector. It develops, manufactures and markets automated solutions (instruments and tests) for sample preparation of bacterial and human DNA from difficult biological samples for use in the fields of infectious diseases, transplantation testing (HLA Typing) and others. The Company’s products include NorDiag Arrow (CE, IVD), which is a compact, automated solution for nucleic acid extractions, as well as NorDiag Bullet, 8 tip config, which is a fully automated sample preparation instrument for molecular diagnostics and can isolate from samples such as urine, swab, faces, sputum and blood. Its distribution products include Molzym GmbH and Co KG, as well as Hain Lifescience GmbH. Its customers are clinical laboratories, hospitals, research institutes, medical diagnostics and healthcare providers. It is operational through offices and laboratories in Norway, Sweden, Austria and the United States.
Employees
1
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. NORD Stock